Evidence map›Paper›PMID 41859120›Full record

ArticleFrontiers in immunology2026

Pharmacological inhibition of USP18 improves antibacterial responses and the intracellular control of

Qiao Zhang, Zhen Gong, Robert Schnell, Yi Zhong, Paul P Geurink, Volker M Lauschke, Jianping Xie, Stefano Gastaldello, Martin E Rottenberg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qiao ZhangDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Zhen GongDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Robert SchnellDepartment of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Yi ZhongDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Paul P GeurinkDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands.
Volker M LauschkeDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Jianping XieSchool of Life Science, Southwest University, Chongqing, China.
Stefano GastaldelloDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Martin E RottenbergDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Type I interferon (IFN-I) responses correlate with the severity of Tuberculosis. ISG15, a ubiquitin-like protein, regulates immune responses intracellularly by protein posttranslational modification (ISGylation) or extracellularly, in a cytokine-like manner. The ubiquitin specific protease USP18 deconjugates ISG15 from target proteins and is a major negative regulator of IFN-I signaling. Methods: Here we show that Results: The inhibition of USP18 enhanced both IFN-I responses and antimicrobial responses in BMM and increased NF-κB-activation and IL-1β expression. Moreover, the USP18 inhibitors improved the intracellular macrophage control of Discussion: Our results suggest that the pharmacological inhibition of USP18 can be further explored as a therapeutic tool in the control of tuberculosis.

Indexed as

MacrophagesMycobacterium tuberculosisTuberculosisUbiquitin ThiolesteraseAnimalsCytokinesInterferon-betaInterferon Type IInterleukin-1betaMiceMice, Inbred C57BLNF-kappa BSignal TransductionUbiquitinsCytokinesG1p2 protein, mouseInterferon-betaInterferon Type IInterleukin-1betaNF-kappa BUbiquitinsUbiquitin ThiolesteraseUsp18 protein, mouseISG15ISGylationmacrophageMycobacterium tuberculosistype I interferonUSP18

Identifiers

PMID41859120
PMCPMC12996095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.